Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Afatinib + Saracatinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Afatinib||Gilotrif||BIBW 2992|Giotrif||EGFR Inhibitor (Pan) 55 EGFR Inhibitor 2nd gen 5 HER inhibitor (Pan) 6||Gilotrif (afatinib) is a second-generation pan-Egfr inhibitor with activity against EGFR T790M and EGFR exon 19 and 21 deletions, and also inhibits ERBB2 (HER2), ERBB3 (HER3), ERBB4 (HER4) (PMID: 24435321, PMID: 25505694). Gilotrif (afatinib) is FDA approved for use in non-small cell lung cancer patients harboring non-resistant EGFR mutations, including exon 19 deletions, L858R, S768I, G719X, and L861Q, and for patients with metastatic squamous NSCLC (FDA.gov).|
|Saracatinib||AZD0530||BCR-ABL Inhibitor 29 SRC Inhibitor 31||Saracatinib (AZD0530) is a multi-kinase inhibitor with activity against ABL and SRC, which may block proliferation, metastasis, and survival in cancer cells (PMID: 19393585, PMID: 32398945).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|